生物药物产品的填充单元运行:挑战和考虑
Michael Adler1, Andrea Allmendinger2
1ten23 health AG, Mattenstr. 22, 4058 Basel, Switzerland.
Journal of pharmaceutical sciences
|November 22, 2023
概括
本综述涵盖了生物制品的无菌填充技术,详细介绍了系统和超时压力方法. 它强调了粒子形成和吸附等挑战,为工艺开发和可持续的一次性设备使用提供了见解.
科学领域:
- 制药制造业 制药制造业 制药制造业
- 生物技术是生物技术.
- 工艺工程是过程工程.
背景情况:
- 无菌填充完成对于肠道生物制剂至关重要.
- 填充技术显著影响最终药物产品的质量.
- 了解填充过程对于确保产品的安全性和有效性至关重要.
研究的目的:
- 审查在生物填充完成操作中使用的常见和创新的填充技术.
- 分析各种灌装系统的操作原理,优点和缺点.
- 讨论在无菌填充过程中影响产品质量的挑战和考虑因素.
主要方法:
- 关于常用的填充技术的文献综述.
- 对正位移系统 (环静电,活塞,隔膜) 和时间超压填充的分析.
- 讨论诸如粒子形成,吸附和过氧化吸收等挑战.
主要成果:
- 辐射环静电,旋转活塞,滚动隔膜,线性环静电和时间超压填充的概述.
- 识别系统特异性风险,包括蛋白质颗粒的形成和材料磨损.
- 讨论一般挑战,如过氧化的吸收,吸附和针塞.
结论:
- 过程开发和表征对于评估填充过程对产品质量影响至关重要.
- 考虑蛋白质稳定性,颗粒脱落和材料相互作用至关重要.
- 未来的前景包括使用一次性设备,以提高灌业务的可持续性.
相关概念视频
Biopharmaceutics and Pharmacokinetics: Overview
2.1K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.1K
Factors Influencing Drug Absorption: Pharmaceutical Parameters
134
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
134
One-Compartment Open Model for IV Bolus Administration: General Considerations
213
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
213
One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution
278
The one-compartment open model is a simplified approach used in pharmacokinetics to understand the distribution and elimination of a drug administered through an intravenous bolus. This model assumes rapid drug dispersal throughout the body and elimination using a first-order process. Key pharmacokinetic parameters, such as the elimination rate constant (k), half-life (t1/2), and the apparent volume of distribution (Vd), can be estimated from this model. The elimination rate is calculated...
278
One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance
80
Clearance is a key pharmacokinetic parameter that quantifies the volume of body fluid from which a drug is entirely removed within a specific time frame. It is crucial in assessing how a drug is eliminated from the body and has critical clinical applications.
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
80
Bioequivalence: Overview
1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K


